JNJ vs RLMD: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. JNJ and RLMD share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined JNJ and RLMD exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Johnson & Johnson is one of the world's largest healthcare companies, now focused on two core areas after spinning off its consumer-health business (Kenvue). Its Innovative Medicine segment develops and sells branded prescription drugs across oncology, immunology, neuroscience, cardiovascular, and other areas, with major franchises that drive much of its profit. Its MedTech segment makes medical devices and surgical equipment for cardiovascular intervention, orthopedics, surgery, and vision care. J&J makes money by researching, manufacturing, and selling patented pharmaceuticals and devices to hospitals, physicians, pharmacies, and patients worldwide, supported by one of the largest research and development budgets in healthcare. The company is known for its diversification, financial strength, AAA-class balance sheet, and a multi-decade record of raising its dividend, making it a classic defensive blue chip. Founded in 1886 and headquartered in New Brunswick, New Jersey, J&J is a broadly held, large-cap healthcare company valued for stability, income, and a deep drug and device pipeline.

Full JNJ guide

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company based in Coral Gables, Florida, incorporated in Nevada and listed on the Nasdaq Capital Market. It has no approved products and has never generated revenue. Its two programs are NDV-01, a sustained-release formulation of the chemotherapy drugs gemcitabine and docetaxel that is placed directly into the bladder to treat non-muscle invasive bladder cancer (NMIBC), and sepranolone, a neurosteroid being developed first for Prader-Willi syndrome (PWS), with Tourette syndrome and essential tremor as possible later uses. It had 17 employees at the end of 2025 and relies on contract research and manufacturing firms.

Full RLMD guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• JNJ drivers: Innovative Medicine pipeline; MedTech innovation and recovery.
• RLMD drivers: NDV-01's Phase 2 results; The IND filing and Phase 3 RESCUE start.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: J&J faces patent expirations on key drugs, including the eventual loss of exclusivity for major franchises, which requires the pipeline to continually replace lost revenue. For RLMD, the biggest risk is clinical: NDV-01's Phase 2 data come from 48 patients at a single site in Israel with no control arm, and response rates in small open-label studies often fall in larger multi-center trials.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick JNJ if you believe its drivers more; RLMD if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the JNJ and RLMD guides.

JNJ. J&J trades at a valuation typical of a large, defensive healthcare blue chip: a moderate multiple reflecting steady low-to-mid single-digit growth, high margins, and very strong cash generation, plus a discount for litigation and patent-cliff overhangs. The market values its diversification, balance-sheet strength, and long dividend record, pricing it as a stable income-and-quality holding rather than a growth stock.

RLMD. With no revenue, the usual earnings ratios do not apply. The useful comparison is market value against cash: at ~$362 million versus ~$218 million of cash and investments, the market assigns roughly $145 million to NDV-01, sepranolone and the team. Quarterly losses of ~$13 million are modest for a company preparing a Phase 3 program, and interest income is offsetting part of the spend. That premium was far larger in spring 2026, when the shares traded above $7. The next quarterly report, expected in November based on last year's calendar, should show whether spending is ramping as planned.

Headline figures (approximate, early 2026): JNJ shows revenue (ttm) ~$90 billion, operating margin ~25%, net income (ttm) ~$15 billion, p/e (ttm) ~16x; RLMD shows revenue (ttm) $0 (no approved products), net loss (h1 2026) ~$32.0 million, net loss (fy 2025) ~$57.4 million, cash + short-term investments (jun 30, 2026) ~$217.7 million.

JNJ and RLMD are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined JNJ and RLMD exposure against your real portfolio. It is not an investment adviser.